zsp1603
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 16, 2018 (NCT03619616)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
PDGFRB inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05119972 | Phase 1/Phase 2 (Phase 2) | Oct 21, 2021 | Guangdong Raynovent Biotech Co., Ltd |
| NCT03619616 | Phase 1 | Jul 16, 2018 | Central South University, Guangdong Zhongsheng Pharmaceutical Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Guangdong Raynovent Biotech Co., Ltd | For profit | 1 | 1 | 1 | 2021 |
| Guangdong Zhongsheng Pharmaceutical Co., Ltd. | For profit | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1